SG11202101922YA - Highly versatile method for granting new binding specificity to antibody - Google Patents

Highly versatile method for granting new binding specificity to antibody

Info

Publication number
SG11202101922YA
SG11202101922YA SG11202101922YA SG11202101922YA SG11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA SG 11202101922Y A SG11202101922Y A SG 11202101922YA
Authority
SG
Singapore
Prior art keywords
antibody
binding specificity
highly versatile
new binding
versatile method
Prior art date
Application number
SG11202101922YA
Inventor
Hiroaki Suga
Junichi Takagi
Original Assignee
Univ Tokyo
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tokyo, Univ Osaka filed Critical Univ Tokyo
Publication of SG11202101922YA publication Critical patent/SG11202101922YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
SG11202101922YA 2018-07-31 2019-07-31 Highly versatile method for granting new binding specificity to antibody SG11202101922YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018144345 2018-07-31
PCT/JP2019/030081 WO2020027224A1 (en) 2018-07-31 2019-07-31 Super versatile method for imparting new binding specificity to antibody

Publications (1)

Publication Number Publication Date
SG11202101922YA true SG11202101922YA (en) 2021-03-30

Family

ID=69231246

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101922YA SG11202101922YA (en) 2018-07-31 2019-07-31 Highly versatile method for granting new binding specificity to antibody

Country Status (11)

Country Link
US (1) US20210317233A1 (en)
EP (1) EP3831846A4 (en)
JP (2) JP7303527B2 (en)
KR (1) KR20210038580A (en)
CN (1) CN112566928A (en)
AU (1) AU2019313945A1 (en)
CA (1) CA3111050A1 (en)
EA (1) EA202190397A1 (en)
IL (1) IL280500A (en)
SG (1) SG11202101922YA (en)
WO (1) WO2020027224A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022009992A1 (en) * 2020-07-10 2022-01-13
WO2023179370A1 (en) * 2022-03-21 2023-09-28 The Hong Kong Polytechnic University Peptidic bispecific antibody, methods for preparation and uses thereof
WO2024048683A1 (en) * 2022-08-30 2024-03-07 ミラバイオロジクス株式会社 Artificial protein and pharmaceutical composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180343B1 (en) * 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
JP2003533187A (en) 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド Modified peptide containing Fc domain as therapeutic agent
EA011879B1 (en) * 2004-09-24 2009-06-30 Эмджин Инк. MODIFIED Fc MOLECULES
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AT503902B1 (en) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
US9090668B2 (en) 2007-03-26 2015-07-28 The University Of Tokyo Process for synthesizing cyclic peptide compound
EP2492344B1 (en) 2009-10-22 2016-04-06 PeptiDream Inc. Rapid display method in translational synthesis of peptide
JP6004399B2 (en) 2010-12-03 2016-10-05 国立大学法人 東京大学 Peptide having stabilized secondary structure, peptide library, and production method thereof
EA036814B9 (en) 2011-11-28 2021-12-27 Мерк Патент Гмбх Anti-pd-l1 antibody (embodiments), composition comprising this antibody and use thereof
EP4310191A3 (en) * 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
EP2912058A1 (en) * 2012-10-23 2015-09-02 The Board of Regents of The University of Texas System Antibodies with engineered igg fc domains
JOP20140087B1 (en) * 2013-03-13 2021-08-17 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
JP6754997B2 (en) 2013-08-26 2020-09-16 国立大学法人 東京大学 A large cyclic peptide, a method for producing the same, and a screening method using a large cyclic peptide library.
CN106589129B (en) * 2016-12-30 2021-03-05 上海近岸生物科技有限公司 Tri-functional molecule combined with CD19, CD3 and CD28 and application thereof
SG11202000801QA (en) * 2017-07-31 2020-02-27 Univ Tokyo Highly versatile method of presenting cyclic peptide on protein structure

Also Published As

Publication number Publication date
JP7303527B2 (en) 2023-07-05
US20210317233A1 (en) 2021-10-14
CN112566928A (en) 2021-03-26
WO2020027224A1 (en) 2020-02-06
KR20210038580A (en) 2021-04-07
JPWO2020027224A1 (en) 2021-08-02
EP3831846A1 (en) 2021-06-09
EA202190397A1 (en) 2021-06-11
AU2019313945A1 (en) 2021-03-18
EP3831846A4 (en) 2022-05-11
CA3111050A1 (en) 2020-02-06
JP2023093637A (en) 2023-07-04
IL280500A (en) 2021-03-25

Similar Documents

Publication Publication Date Title
IL276537A (en) Antibodies binding to gprc5d
ZA202203250B (en) Cd3 binding antibodies
IL287613A (en) Antibodies binding to gprc5d
IL283939A (en) Antibodies binding to cd3
ZA201808209B (en) Antibody for binding to interleukin 4 receptor
IL263840A (en) Cd3 binding antibodies
HK1252862A1 (en) Antibody molecules which bind cd45
IL274370A (en) Single domain antibodies that bind to cd137
IL256870B (en) Constructs for bispecific antibodies binding cd70 and cd3 and uses thereof
EP3294766C0 (en) Humanized antibody or fragment thereof specific for cd3
HK1250737A1 (en) Antibody molecules which bind cd79
SG11201709908QA (en) Method for quantifying monoclonal antibody
IL292727A (en) Multispecific antibody
IL282590A (en) Heavy chain antibodies binding to cd38
IL280500A (en) Super versatile method for imparting new binding specificity to antibody
SG11201800326YA (en) Anti-aggrus monoclonal antibody, domain in aggrus which is required for binding to clec-2, and method for screening for aggrus-clec-2 binding inhibitor
EP3458077A4 (en) Methods for making novel antigen binding domains
IL269394A (en) Antibodies binding to steap-1
IL292799A (en) Anti-siglec-9 antibody molecules
IL277056A (en) Methods for purifying antibodies
EP3623387A4 (en) Monoclonal antibody specifically binding to mrs
GB201718734D0 (en) Single domain antibodies that bind to CD137